These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23075734)

  • 1. Overexpression of enhancer of zests homolog 2 in lymphoma.
    Guo SQ; Zhang YZ
    Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation.
    Qi Y; Zhang X; Kang Y; Wu J; Chen J; Li H; Guo Y; Liu B; Shao Z; Zhao X
    Mol Biosyst; 2015 Jul; 11(7):1980-6. PubMed ID: 25947258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.
    Kanduri M; Sander B; Ntoufa S; Papakonstantinou N; Sutton LA; Stamatopoulos K; Kanduri C; Rosenquist R
    Epigenetics; 2013 Dec; 8(12):1280-8. PubMed ID: 24107828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
    Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
    Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
    Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
    Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
    Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
    Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 in normal and malignant hematopoiesis.
    Lund K; Adams PD; Copland M
    Leukemia; 2014 Jan; 28(1):44-9. PubMed ID: 24097338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
    Barsotti AM; Ryskin M; Rollins RA
    Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
    Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
    Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
    Wen Y; Cai J; Hou Y; Huang Z; Wang Z
    Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
    Bian EB; Li J; He XJ; Zong G; Jiang T; Li J; Zhao B
    Expert Opin Ther Targets; 2014 Oct; 18(10):1197-206. PubMed ID: 25046371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
    Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
    Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
    Yamagishi M
    Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
    Romanchikova N; Trapencieris P
    Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.